ReShape Lifesciences (RSLS) Stock Price, News & Analysis

Company Overview

ReShape Lifesciences, headquartered in San Clemente, California, is a medical device company specializing in minimally invasive and non‐surgical therapies for obesity management and body contouring. The company’s core product portfolio includes endoscopic intragastric balloon systems that support physician‐led weight‐loss programs and non‐surgical cryolipolysis‐based devices for targeted adipose reduction without surgery.

Under its ReShape Interventions division, the company markets a dual intragastric balloon system engineered to occupy gastric space, promote early satiety and aid comprehensive diet and lifestyle regimens. Through its OSPREY Medical division, ReShape provides non‐invasive body‐contouring platforms that harness controlled cooling and compression to reduce subcutaneous fat in outpatient aesthetic settings.

Founded in 2010, ReShape Lifesciences has expanded beyond the United States to serve outpatient clinics and healthcare professionals in select European markets. The company partners with gastroenterologists, bariatric specialists and aesthetic practitioners to integrate its device technologies into multidisciplinary care pathways for patients seeking weight management and body‐shaping solutions.

ReShape Lifesciences is guided by a leadership team with extensive expertise in medical device research, clinical development and regulatory compliance. The company continues to invest in product innovation and clinical studies aimed at enhancing the safety and efficacy of its minimally invasive and non‐invasive therapies in the growing obesity and aesthetic care markets.

Key Stats

• Today's Range: $2.80 to $4.65
• 50-Day Range: $3.16 to $15.68
• 52-Week Range: $1.87 to $303.25
• Volume: 13.69 million shs
• Average Volume: 3.32 million shs
• Market Capitalization: $8.49 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RSLS Stock Analysis - Frequently Asked Questions

How have RSLS shares performed this year?

ReShape Lifesciences' stock was trading at $446.00 at the beginning of the year. Since then, RSLS shares have decreased by 99.3% and is now trading at $3.1550.

How were ReShape Lifesciences' earnings last quarter?

ReShape Lifesciences Inc. (NASDAQ:RSLS) issued its quarterly earnings data on Thursday, August, 14th. The medical device company reported ($9.00) earnings per share (EPS) for the quarter. The medical device company earned $1.24 million during the quarter. ReShape Lifesciences had a negative trailing twelve-month return on equity of 547.65% and a negative net margin of 69.71%.

When did ReShape Lifesciences' stock split?

ReShape Lifesciences's stock reverse split on Monday, August 18th 2025.The 1-4 reverse split was announced on Wednesday, August 13th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 15th 2025. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

How do I buy shares of ReShape Lifesciences?

Shares of RSLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ReShape Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ReShape Lifesciences investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Digital Turbine (APPS), Nano Dimension (NNDM), CrowdStrike (CRWD) and

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/16/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:RSLS
• CIK: 1371217
• Web: www.reshapelifesciences.com
• Phone: (949) 429-6680
• Fax: N/A
• Employees: 50
• Year Founded: 2002

Profitability

• EPS (Trailing Twelve Months): ($108.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.13 million
• Net Margins: -69.71%
• Pretax Margin: -47.82%
• Return on Equity: -547.65%
• Return on Assets: -79.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.53
• Quick Ratio: 0.91

Sales & Book Value

• Annual Sales: $8.01 million
• Price / Sales: 1.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($8.66) per share
• Price / Book: -0.36

Miscellaneous

• Outstanding Shares: 2,690,000
• Free Float: 2,386,000
• Market Cap: $8.49 million
• Optionable: Not Optionable
• Beta: 1.16